NanoViricides Positions NV-387 as Key Player Against Bird Flu

NanoViricides, Inc. has announced that its antiviral drug candidate, NV-387, could be crucial in combating a potential bird flu pandemic. The company believes that the H5N1 Influenza A virus is unlikely to develop resistance to this drug. NV-387 mimics essential host-side features that are critical for the virus's survival, regardless of mutations.

The World Health Organization has noted that certain genetic markers in human H5N1 cases might reduce the effectiveness of current antiviral drugs. NV-387 has shown greater efficacy than existing influenza treatments in animal studies. Additionally, the drug offers a broad-spectrum antiviral capability against various viruses, including COVID-19 and RSV.

NV-387 has completed a Phase I trial smoothly and is set for further Phase II clinical trials targeting several respiratory infections and MPOX.